

Rashmi Chugh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4613973/publications.pdf>

Version: 2024-02-01

67
papers

3,515
citations

257450

24
h-index

144013

57
g-index

70
all docs

70
docs citations

70
times ranked

6728
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	27.8	685
2	Chordoma: The Nonsarcoma Primary Bone Tumor. <i>Oncologist</i> , 2007, 12, 1344-1350.	3.7	342
3	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017, 7, 620-629.	9.4	321
4	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4541-4547.	1.6	293
5	Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. <i>Clinical Cancer Research</i> , 2010, 16, 4884-4891.	7.0	213
6	Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. <i>Journal of Clinical Oncology</i> , 2009, 27, 3148-3153.	1.6	210
7	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , 2015, 25, 1372-1381.	5.5	139
8	Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. <i>Cancer</i> , 2017, 123, 90-97.	4.1	101
9	Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3597-3604.	1.6	87
10	SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. <i>Cancer</i> , 2016, 122, 868-874.	4.1	80
11	Activation of Wnt/ β -Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. <i>Cancer Research</i> , 2016, 76, 5040-5053.	0.9	70
12	<i>si</i> -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 3660-3670.	1.6	69
13	Randomized Phase II Evaluation of 6 g/m ² of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m ² of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 105-112.	1.6	65
14	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	7.1	65
15	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58
16	Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. <i>European Journal of Cancer</i> , 2012, 48, 1347-1353.	2.8	50
17	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	1.8	45
18	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). <i>Sarcoma</i> , 2019, 2019, 1-8.	1.3	45

#	ARTICLE	IF	CITATIONS
19	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQq1.d 0.784334 rgBT	0.784334	4
20	A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.. Journal of Clinical Oncology, 2014, 32, 2528-2528.	1.6	42
21	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma, 2020, 2020, 1-8.	1.3	33
22	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Investigational New Drugs, 2020, 38, 1421-1429.	2.6	33
23	Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases. Sarcoma, 2019, 2019, 1-6.	1.3	31
24	Psychosocial, behavioral, and supportive interventions for pediatric, adolescent, and young adult cancer survivors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103291.	4.4	31
25	A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. European Journal of Cancer, 2015, 51, 1794-1802.	2.8	29
26	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncology, 2018, 4, 814.	7.1	26
27	Current clinical management of primary cardiac sarcoma. Expert Review of Anticancer Therapy, 2020, 20, 45-51.	2.4	23
28	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.. Journal of Clinical Oncology, 2014, 32, 7522-7522.	1.6	22
29	Wnt/ β -catenin-activated Ewing sarcoma cells promote the angiogenic switch. JCI Insight, 2020, 5, .	5.0	21
30	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer, 2021, 127, 1301-1310.	4.1	20
31	Next generation sequencing of extraskeletal myxoid chondrosarcoma. Oncotarget, 2017, 8, 21770-21777.	1.8	20
32	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb004) in metastatic soft-tissue sarcomas. Cancer, 2019, 125, 2445-2454.	4.1	19
33	Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer, 2007, 109, 2315-2322.	4.1	18
34	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	1.6	17
35	A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma. Oncotarget, 2016, 7, 61775-61788.	1.8	16
36	Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2500-2500.	1.6	14

#	ARTICLE	IF	CITATIONS
37	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	1.3	13
38	Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 390-404.	3.8	12
39	Nonepithelial malignancies of the breast. <i>Oncology</i> , 2004, 18, 665-73; discussion 673-6.	0.5	11
40	Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. <i>Oncologist</i> , 2022, 27, 595-599.	3.7	9
41	Canonical Wnt/ β -catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma. <i>Rare Tumors</i> , 2018, 10, 203636131881343.	0.6	8
42	Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. <i>Cancer</i> , 2021, 127, 1311-1317.	4.1	8
43	Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults.. <i>Journal of Clinical Oncology</i> , 2017, 35, 101-101.	1.6	7
44	Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience. <i>Frontiers in Oncology</i> , 2019, 9, 1523.	2.8	6
45	Experimental Therapies and Clinical Trials in Bone Sarcoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 715-725.	4.9	5
46	Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib. <i>Journal of Clinical and Diagnostic Research JCDR</i> , 2014, 8, QD01-2.	0.8	5
47	Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas. <i>Journal of Surgical Oncology</i> , 2022, 125, 1292-1300.	1.7	5
48	Pharmacotherapy of sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1953-1963.	1.8	4
49	Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3579-3587.	4.3	4
50	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4585-TPS4585.	1.6	3
51	Aldoxorubicin in Sarcoma. <i>JAMA Oncology</i> , 2015, 1, 1280.	7.1	2
52	SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy. <i>BMC Cancer</i> , 2016, 16, 663.	2.6	2
53	The potential of emerging therapeutics for epithelioid sarcoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 983-989.	0.8	2
54	Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing's sarcoma. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 1023-1028.	2.5	2

#	ARTICLE	IF	CITATIONS
55	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).. Journal of Clinical Oncology, 2021, 39, 11563-11563.	1.6	2
56	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. Journal of Clinical Oncology, 2015, 33, 11057-11057.	1.6	2
57	Surgical Management of Rhabdomyosarcoma of the Nasal Cavity and Paranasal Sinuses: Analysis of Operative Indications, Settings, and Outcomes. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 350-358.	0.8	2
58	A retrospective analysis of patients with soft tissue sarcoma treated long-term with trabectedin.. Journal of Clinical Oncology, 2015, 33, 10551-10551.	1.6	1
59	Systemic Therapies for Locally Recurrent or Metastatic Disease. , 2018, , 399-409.		0
60	Late relapse in soft tissue sarcoma: Prognostic factors for recurrence after 3 years.. Journal of Clinical Oncology, 2014, 32, 10570-10570.	1.6	0
61	The who and what of imaging in sarcoma and correlation with survival.. Journal of Clinical Oncology, 2015, 33, 10511-10511.	1.6	0
62	Radiation-associated versus sporadic osteosarcoma: A single-institution experience.. Journal of Clinical Oncology, 2017, 35, 11018-11018.	1.6	0
63	Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-papamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).. Journal of Clinical Oncology, 2018, 36, TPS11589-TPS11589.	1.6	0
64	Inferior vena cava leiomyosarcoma: A single-institution experience.. Journal of Clinical Oncology, 2018, 36, e23556-e23556.	1.6	0
65	Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.. Journal of Clinical Oncology, 2018, 36, 6600-6600.	1.6	0
66	A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma.. Journal of Clinical Oncology, 2018, 36, 11528-11528.	1.6	0
67	Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers.. Journal of Clinical Oncology, 2019, 37, e23096-e23096.	1.6	0